Artificial intelligence (AI) now features prominently in boardroom and executive discussions across the life sciences industry. The attention is understandable: AI has the potential to fundamentally reshape how companies discover, develop and deliver new therapies. Its effect on both business performance and patient outcomes will be substantial and far-reaching.


